Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 18 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2013 Planned end date changed from 1 Jul 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 23 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.